Gemini Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies that modulate the complement system to treat aging-related and inflammatory diseases. Founded in 2016 and headquartered in Boston, Massachusetts, the company leverages its proprietary chemistry platform to create small-molecule and biologic complement C3 inhibitors. Gemini’s research is grounded in the biology of complement activation, with the goal of addressing unmet medical needs that arise from dysregulated immune processes.
The company’s lead ophthalmology candidate, GEM103, is an intravitreal formulation designed to restore complement factor I (CFI) activity in patients with geographic atrophy, an advanced form of age-related macular degeneration. Gemini has initiated clinical trials in North America and Europe to evaluate the safety, tolerability, and preliminary efficacy of GEM103 in restoring complement homeostasis in the retina. In parallel, the company is advancing systemic C3 inhibitors aimed at conditions such as C3 glomerulopathy and paroxysmal nocturnal hemoglobinuria, where overactivation of the complement cascade plays a central role.
Gemini Therapeutics collaborates with leading academic institutions, contract research organizations, and clinical sites to drive its programs from preclinical research through late-stage development. Its team includes experts in complement biology, medicinal chemistry, and translational medicine, working in labs in Boston and partnering with CROs in Europe and Asia. The company’s translational research efforts aim to refine biomarkers of complement activity and patient selection strategies to enhance the precision of its clinical trials.
Under the leadership of President and Chief Executive Officer David Valentine, Gemini Therapeutics is committed to advancing its pipeline through strategic partnerships and internal innovation. The company’s management team brings extensive experience in drug development, regulatory affairs, and commercialization within the biotech sector. As Gemini progresses its programs, it seeks to deliver pioneering therapies that address the root causes of complement-mediated diseases and improve outcomes for patients worldwide.
AI Generated. May Contain Errors.
Free GMTX Stock Alerts